Friday, July 29, 2016
Pfizer and Western Oncolytics announce immuno-oncology research collaboration to investigate novel oncolytic virus technology.
Following completion of Phase I trials, Pfizer has an exclusive option to acquire WO-12.
Under terms of agreement, Pfizer and Western Oncolytics will collaborate on preclinical, clinical development of WO-12 through Phase I trials.
Financial terms of agreement were not disclosed.
Following completion of Phase I trials, Pfizer has an exclusive option to acquire WO-12.
Source : in.reuters.com
